BOARD OF DIRECTORS
Aiphi Nguyen, PharmD, CEO & Co-Founder
Ms Aiphi Nguyen has a twofold pharmaceutical and financial background and has more than 15 years combined experience. She held various positions in marketing and sales with Bristol Myers Squibb before steering in the investment bank sector where she served as a business and financial analyst consultant in the life sciences sector. Prior to Skymab, she had on her credit the creation of two successful companies (Etsi communication and dixhuit Production).
Ms Aiphi Nguyen holds a Doctorate in Pharmacy of the University Claude Bernard, a MBA of IAE (Institut d’Administration des Entreprises from Sorbonne University), a master of science in Finance of ESCP Europe and Challenge Plus of HEC Startup Program.
Christophe Pasik, MD, Co-Founder
Dr. Christophe Pasik is a co-founder and investor of Skymab.
He has more than 25 years experience in the pharmaceutical industry (Merck Lipha, RP Scherer, Pharmacia, Pfizer). He co-founded KEOCYT and served as the president as well as in many other companies, mainly in the healthcare sector. As a seasonned business angel, he is currently an active investor in a dozen start up IN HEALTHCARE and mentors young entrepreneurs. Mr Christiphe CHRISTOPHE Pasik holds a Medecine Doctorate.
Henri Benech, PharmD, PhD, Co-Founder
Henri Bénech is a pharmacist with a PhD in Pharmacology and a habilitation to supervise research from Paris-Sud and Paris-Descartes Universities. Henri has worked for 20 years as a senior researcher in drug metabolism and pharmacokinetics at the CEA. He conducted researchers on fate of magnesium in human using stable isotopes, on intracellular pharmacology of anti-HIV drugs and he developed a metabolic diagnostic test for treatment individualization.
Later, Henri moved to the Technological Transfer Office of its organization to develop the technological transfer and to set-up spin-off, with a high success rate. Henri is a co-founder of CERES Brain Therapeutics, a biotech company dedicated to development of the treatment for cerebral rare diseases where he serves as the COO. Henri is also a member of the French National Academy of Pharmacie. Henri is an expert in medicines pricing since he has been rapporteur at the French comity pricing medicine for 5 years.
Hugues Dolgos - CEO of NMS Group S.p.A
Hugues Dolgos is a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology. Dr. Dolgos joins from Servier where he was Global Head of Oncology and a member of the R&D leadership team. Prior to that, he held notable positions at Merck KGaA as Vice President and Head of R&D Strategy PMO, Quantitative Pharmacology and Drug Disposition, setting up strategic directions to best select and ultimately deliver candidate drugs even beyond approval. During the past decades, he has been leading large teams at international top-tier companies like AstraZeneca and Merck KGaA on R&D strategy, R&D governance and capabilities building including Modeling&Simulation, DMPK, Clinical Pharmacology, Bioinformatics, R&D digital, forming alliance, driving changes and creating values for the organizations. Dr. Dolgos is also a Board member of Skymab.
He holds a Doctor of Pharmacy degree from the University of Pharmacy (Paris V), a Post Graduate degree of Analytical Chemistry (DEA) from University Pierre & Marie Curie (Paris VI) and an MS in Medical Sciences from Paris V and Paris VI Universities.